<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45628">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512250</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0667</org_study_id>
    <nct_id>NCT02512250</nct_id>
  </id_info>
  <brief_title>Swiss Hemophilia Registry</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Hemophilia Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Hemophilia Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Swiss Hemophilia Registry will collect data on the prophylactic and therapeutic use of
      factor concentrates in patients with hemophilia and other severe bleeding disorders in
      Switzerland.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Number of incidence of disease and inhibitor development</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of factor concentrate consumption</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Hemophilia and Other Severe Bleeding Disorders</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Registry</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hemophilia and other severe bleeding disorders
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of hemophilia or other severe bleeding disorders. Signed inform consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Manuela Albisetti, MD</last_name>
    <phone>+41 44 266 71 38</phone>
    <email>manuela.albisetti@kispi.uzh.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reta Malär, MD</last_name>
      <phone>+ 41 81 256 60 41</phone>
      <email>reta.malaer@sgr.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuela Albisetti, MD</last_name>
      <phone>+ 41 44 266 71 38</phone>
      <email>manuela.albisetti@kispi.uzh.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8090</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Brand, MD</last_name>
      <phone>.+41 44 255 22 94</phone>
      <email>brigit.brand@sz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 30, 2015</lastchanged_date>
  <firstreceived_date>July 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
